Advertisement

Current Oncology Reports

, Volume 3, Issue 2, pp 179–184 | Cite as

Multiple daily fractionation radiotherapy schedules in lung cancer

  • Craig A. Schulz
  • Paul M. Harari
  • Minesh P. Mehta
Article

Abstract

Lung cancer is the number one worldwide cancer killer, and in spite of therapeutic advances, the overall impact on survival has remained very modest. For both small and non-small-cell lung cancer, treatment trends have shifted toward combined-modality approaches, chemotherapy for the control of systemic micrometastases, and radiotherapy for intrathoracic control. However, on both counts, rates of failure remain unacceptably high, and several novel strategies are currently being explored. The use of altered fractionation, including multiple daily fractions, reflects one approach for modifying radiotherapy. The two most common approaches are hyperfractionation and acceleration, the former designed to reduce late normal tissue toxicities and the latter to counteract accelerated tumor repopulation. Recent randomized trials suggest that such approaches may result not only in lowered rates of intrathoracic failure but also in improved survival.

Keywords

Radiat Oncol Biol Phys Radiation Therapy Oncology Group Thoracic Radiotherapy Biological Equivalent Dose Altered Fractionation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lechevalier T, Arriagada R, Quoix E, et al.: Radiotherapy alone vs. combined chemotherapy and radiotherapy in nonresectable, non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83:417–423.CrossRefGoogle Scholar
  2. 2.
    Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992, 13:890–895.Google Scholar
  3. 3.
    Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1998, 327:1618–1624.CrossRefGoogle Scholar
  4. 4.
    Thames HD, Peters LJ, Withers HR, et al.: Accelerated fractionation vs. hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys 1983, 9:127–138.PubMedGoogle Scholar
  5. 5.
    Wilson GD, Saunders MI, Dische S, et al.: Direct comparison of bromodeoxyuridine and Ki-67 labeling indices in human tumors. Cell Prolif 1996, 29:141–152.PubMedCrossRefGoogle Scholar
  6. 6.
    Fowler JF, Chappell R: Non-small cell lung tumors repopulate rapidly during radiation therapy [letter; comment]. Int J Radiat Oncol Biol Phys 2000, 46:516–517. Demonstrates survival loss of 1.6% per day of treatment prolongation beond 6 weeks.PubMedCrossRefGoogle Scholar
  7. 7.
    JD, Pajak TF, Aspell S, et al.: Interruptions of high dose radiation therapy decrease long-term survival of favorable fatients with unresectable non-small cell carcinoma of the lung: analysis of 1,244 cases from three Radiation Therapy Oncology Group (RTOG) Trials. Int J Radiat Oncol Biol Phys 1993, 27:493–498.Google Scholar
  8. 8.
    Sause W, Scott C, Taylor S, et al.: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer. J Natl Cancer Inst 1995, 87:198–205.PubMedCrossRefGoogle Scholar
  9. 9.
    Byhardt RW, Pajak F, Emami B, et al.: A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno and large cell carcinoma of the lung, report of Radiation Therapy Oncology Group 8407. Int J Radiat Oncol Biol Phys 1993, 26:459–468.PubMedGoogle Scholar
  10. 10.
    Saunders M, Dische S, Barrett A, et al.: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Committee. Radiother Oncol 1999, 52:137–148. Recent report that confirms the superiority of CHART.PubMedCrossRefGoogle Scholar
  11. 11.
    Mehta MP, Tannehill SP, Adak S, et al.: Phase II trial of hyperfractionated accelerated radiation therapy (HART) for nonresectable non-small cell lung cancer: results of ECOG 4593. J Clin Oncol 1998, 16:3518–3523.PubMedGoogle Scholar
  12. 12.
    Dillman RO, Herndon J, Seagren SL, et al.: Improved survival in stage III non-small cell lung cancer: 7-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210–1215.PubMedCrossRefGoogle Scholar
  13. 13.
    Schaake-Konig C, Van Den Bogaert W, Dalesio O, et al.: Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. N Engl J Med 1992, 326:524–530.CrossRefGoogle Scholar
  14. 14.
    Byhardt RW, Scott CB, Ettinger DS, et al.: Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small cell lung cancer: results of Radiation Therapy Oncology Group (RTOG) 90-15. Cancer 1995, 75:2337–2344.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee JS, Scott C, Komaki R, et al.: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 1996, 14:1055–1064.PubMedGoogle Scholar
  16. 16.
    Curran WJ, Scott C, Langer C, et al.: Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non small cell lung cancer: initial report of the Radiation Therapy Oncology Group (RTOG) 9410 [abstract]. Proc ASCO 2000, 19:484a. Abstract report of preliminary findings for RTOG trial.Google Scholar
  17. 17.
    Jeremic B, Shibamoto Y, Acimovic L, Milosavljevic S: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clinic Oncol 1995, 13:452–458.Google Scholar
  18. 18.
    Jeremic B, Shibamoto Y, Acimovic L, Milosavljevic S: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized trial. J Clin Oncol 1996, 14:1065–1070.PubMedGoogle Scholar
  19. 19.
    Turrisi AT III, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265–271. Report on accelerated fractionation trial that shows significantly improved overall survival compared with results for concurrent once-daily treatment, as well as improved toxicity, for limited-stage small-cell lung cancer.PubMedCrossRefGoogle Scholar
  20. 20.
    Le Pechoux C, Arriagada R, Le Chevalier T, et al.: Concurrent cisplatin-vindesine and hyperfractionated thoracic radiotherapy in locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1996, 35:519–525.PubMedCrossRefGoogle Scholar
  21. 21.
    Byhardt RW, Scott C, Scott C, et al.: Response toxicity failure patterns and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998, 42:469–478.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2001

Authors and Affiliations

  • Craig A. Schulz
    • 1
  • Paul M. Harari
    • 1
  • Minesh P. Mehta
    • 1
  1. 1.Department of Human OncologyUniversity of Wisconsin Medical SchoolMadisonUSA

Personalised recommendations